Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2007
At a glance
- Drugs Fezakinumab; Fezakinumab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 12 Dec 2007 Status changed from in progress to completed.
- 09 Oct 2007 Status changed from recruiting to in progress.
- 07 May 2007 New trial record.